ThromboGenics/Alcon's Jetrea gets strongest AMNOG endorsement yet from German HTA
This article was originally published in Scrip
ThromboGenics/Alcon's Jetrea (ocriplasmin) for vitreomacular traction has won the strongest endorsement yet from German health technology appraisal institute IQWiG for a drug passing through the tough AMNOG pricing and reimbursement system. The institute thinks it offers "major" and "considerable" benefits over standard of care, which bodes well for the price that the firm will eventually be able to command in Germany.
You may also be interested in...
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.